FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases

• 1. 用于治疗高胆固醇血症、动脉粥样硬化、冠心病、胆结石、肥胖症和其它心血管疾病的鸟苷酸环化酶的激动剂 [P] . 中国专利： CN105963676B . 2020.02.18
• 2. 用于治疗高胆固醇血症、动脉粥样硬化、冠心病、胆结石、肥胖症和其它心血管疾病的鸟苷酸环化酶的激动剂 [P] . 中国专利： CN102858361B . 2016.08.03
• 3. Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist /inverse agonist [P] . ZA200805764B . 2009-08-26

  机译： 使用降胆固醇剂和H3受体拮抗剂/反向激动剂治疗非酒精性脂肪肝

• 4. Treatment of nonalcoholic fatty liver disease using cholesterol-lowering agents and H3 receptor antagonists / inverse agonists [P] . 日本专利： JP2009521452A . 2009-06-04

  机译： 使用降胆固醇药和H3受体拮抗剂/反向激动剂治疗非酒精性脂肪肝

• 5. TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE USING CHOLESTEROL LOWERING AGENTS AND H3 RECEPTOR ANTAGONIST/INVERSE AGONIST. [P] . MX2008008340A . 2008-09-03

  机译： 使用胆固醇降糖剂和H3受体拮抗剂/逆激动剂治疗非酒精性脂肪肝疾病。

• 1. Serum non-high-density lipoprotein cholesterol level is increased in Chinese patients with nonalcoholic fatty liver disease [J] . Si-Yu Shao, Yi-Lan Wang, Li-Min Feng, 国际肝胆胰疾病杂志（英文版） . 2020,第006期
• 2. Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease [J] . Ornellade Bari, Brent A.Neuschwander-Tetri, MinLiu, Journal of lipids . 2012,第12期
• 3. Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease [J] . de Bari Ornella, Neuschwander-Tetri Brent A., Liu Min, Journal of lipids . 2012,第12期
• 4. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) [J] . David C. Tully, Paul V. Rucker, Donatella Chianelli, Journal of Medicinal Chemistry . 2017,第24期
• 5. A Deep Learning Approach for Classifying Nonalcoholic Steatohepatitis Patients from Nonalcoholic Fatty Liver Disease Patients Using Electronic Medical Records [C] . Pradyumna Byappanahalli Suresha, Yunlong Wang, Cao Xiao, Health Intelligence Workshop;Association for the Advancement of Artificial Intelligence Annual Conference . 2020
• 6. Relationships between hyperleptinemia, hyperinsulinemia, hypertriglyceridemia and elevations in markers of liver disease for nonalcoholic fatty liver disease in Hispanic children. [D] . Patel, Bhavin. 2003
• 7. Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease [O] . Ornella de Bari, Brent A. Neuschwander-Tetri, Min Liu, 2012
• 8. Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease [O] . de Bari, Ornella, Neuschwander-Tetri, Brent A., Liu, Min, 2012

• 1. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic(type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease [J] . Bharat K Puchakayala ,Siddharth Verma ,Pushpjeet Kanwar . 世界肝病学杂志：英文版（电子版） . 2015,第25期
• 2. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease [J] . Hyun Jung Lee ,Jong Eun Yeon ,Eun Jung Ko . 世界胃肠病学杂志：英文版 . 2015,第45期
• 3. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? [J] . Munechika Enjoji ,Makoto Nakamuta . 世界胃肠病学杂志：英文版 . 2010,第7期
• 4. PNPLA3 I148M variant in nonalcoholic fatty liver disease:Demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis [J] . Li-Zhen Chen ,Yong-Ning Xin ,Ning Geng . 世界胃肠病学杂志：英文版 . 2015,第3期
• 5. GLP-1受体激动剂治疗2型糖尿病合并非酒精性脂肪肝有效性的系统评价和meta分析 [C] . 汤智慧 ,蔡乐 ,王东晓 . 2016年中国药学大会暨第十六届中国药师周 . 2016
• 6. 肌肉减少症与非酒精性脂肪肝及胆结石疾病的关系研究 [A] . 淦达 . 2020